Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Market Cap	2.92B -6.7%
Revenue (ttm)	773.05M +3.2%
Net Income	185.18M +40.0%
EPS	3.62 +39.9%
Shares Out	51.14M
PE Ratio	15.76
Forward PE	19.59
Dividend	0.96 (1.65%)
Ex-Dividend Date	Jul 13, 2026

Volume	90,765
Open	57.60
Previous Close	57.05
Day's Range	57.60 - 59.25
52-Week Range	53.10 - 86.70
Beta	0.27
Analysts	Buy
Price Target	74.36 (+27.88%)
Earnings Date	Nov 5, 2026

About BME:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Expr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 2,470
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ROVI

Financial Performance

In 2025, BME:ROVI's revenue was 743.48 million, a decrease of -2.65% compared to the previous year's 763.75 million. Earnings were 140.44 million, an increase of 2.60%.

Analyst Summary

According to 9 analysts, the average rating for ROVI stock is "Buy." The 12-month stock price target is €74.36, which is an increase of 27.88% from the latest price.

Price Target

€74.36

(27.88% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 6, 2026

Data Sources Report a data error